Skip to content
CompoundSci
All peptides
Research vial labelled DSIP, a Cognitive peptide studied in preclinical and clinical literature

DSIP

Delta sleep-inducing peptide

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

General profile

Class
Cognitive
Evidence
Early or preclinical only
Studied dose range
100–200 mcg
Frequency in protocols
Nightly
Route
Subcutaneous
Half life
~7 minutes (effect outlasts plasma)
Reconstitution
2 mL bacteriostatic water per 5 mg vial
Storage
Refrigerated, ~30 days

Timing and cycling in the literature

Usually dosed in the bedtime window

Nightly

The entire mechanism of interest is sleep architecture. Dosing outside the pre-sleep window makes no sense.

Reported cycle: 4 weeks on, 2 weeks off

Sleep protocols are short because the goal is to reset a pattern, not to depend on an injection to sleep.

Watch for: Morning grogginess and vivid dreams. Track sleep objectively rather than by feel.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Separate syringesTiming

    DSIP + Semax

    Opposite ends of the day, minimum 8 hours

    One is studied for sedation and slow-wave sleep, the other for alertness. Co-administering them cancels the observable effect of both and tells you nothing.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how DSIP fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature